A novel fixative for immunofluorescence staining of CD133-positive glioblastoma stem cells

Journal of Neuroscience Methods

Volumn 198, Issue 1, 2011, Pages 99-102

  Sherman, Jonathan H ^a   Redpath, Gerard T ^a   Redick, Jan A ^a   Purow, Benjamin W ^a   Laws, Edward R ^b   Jane, John A ^a   Shaffrey, Mark E ^a   Hussaini, Isa M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

1,4 Benzoquinone; CD133; Glioblastoma stem cells; Immunofluorescence

Indexed keywords

1,4 BENZOQUINONE; CD133 ANTIGEN;

ARTICLE; GLIOBLASTOMA; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; BENZOQUINONES; FIXATIVES; GLIOBLASTOMA; GLYCOPROTEINS; INTERMEDIATE FILAMENT PROTEINS; MICE; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PEPTIDES; TUMOR CELLS, CULTURED;

EID: 79955521720     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.03.003     Document Type: Article

References (13)

1. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Research 2007, 67:4010-4015.
2. Beier D., Wischhusen J., Dietmaier W., Hau P., Proescholdt M., Brawanski A., et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathology (Zurich Switzerland) 2008.
3. Brown M.D., Gilmore P.E., Hart C.A., Samuel J.D., Ramani V.A., George N.J., et al. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. The Prostate 2007, 67:1384-1396.
4. Fredens K., Dahl R., Venge P. An immunofluorescent method for a specific demonstration of granulocytes and some of their proteins (ECP and CCP). Histochemistry 1986, 84:247-250.
5. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
6. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
7. Maeda S., Shinchi H., Kurahara H., Mataki Y., Maemura K., Sato M., et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. British Journal of Cancer 2008, 98:1389-1397.
8. Shepherd C.J., Rizzo S., Ledaki I., Davies M., Brewer D., Attard G., et al. Expression profiling of CD133(+) and CD133(-) epithelial cells from human prostate. The Prostate 2008.
9. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Research 2003, 63:5821-5828.
10. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
11. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
12. Wang J., Sakariassen P.O., Tsinkalovsky O., Immervoll H., Boe S.O., Svendsen A., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer 2008, 122:761-768.
13. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clinical Cancer Research 2008, 14:123-129.